Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Emerging Roles of the Mineralocorticoid Receptor in Pathology: Toward New Paradigms in Clinical Pharmacology
Frédéric Jaisser, Nicolette Farman, Rhian M. Touyz
Pharmacological Reviews (2015) Vol. 68, Iss. 1, pp. 49-75
Open Access | Times Cited: 289

Showing 1-25 of 289 citing articles:

Duchenne muscular dystrophy
Dongsheng Duan, Nathalie Goemans, Shin’ichi Takeda, et al.
Nature Reviews Disease Primers (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 802
The renin‐angiotensin‐aldosterone system and its suppression
Marisa K. Ames, Clarke E. Atkins, Bertram Pitt
Journal of Veterinary Internal Medicine (2019) Vol. 33, Iss. 2, pp. 363-382
Open Access | Times Cited: 365
Cerebral Vascular Disease and Neurovascular Injury in Ischemic Stroke
Xiaoming Hu, T. Michael De Silva, Jun Chen, et al.
Circulation Research (2017) Vol. 120, Iss. 3, pp. 449-471
Open Access | Times Cited: 361
Importance of the brain corticosteroid receptor balance in metaplasticity, cognitive performance and neuro-inflammation
E. R. de Kloet, Onno C. Meijer, Alejandro F. De Nicola, et al.
Frontiers in Neuroendocrinology (2018) Vol. 49, pp. 124-145
Open Access | Times Cited: 255
Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis
Jonatan Barrera‐Chimal, Sophie Girerd, Frédéric Jaisser
Kidney International (2019) Vol. 96, Iss. 2, pp. 302-319
Open Access | Times Cited: 188
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
Luís M. Ruilope, Rajiv Agarwal, Stefan D. Anker, et al.
American Journal of Nephrology (2019) Vol. 50, Iss. 5, pp. 345-356
Open Access | Times Cited: 185
Mineralocorticoid receptor antagonists in diabetic kidney disease — mechanistic and therapeutic effects
Jonatan Barrera‐Chimal, Ixchel Lima‐Posada, George L. Bakris, et al.
Nature Reviews Nephrology (2021) Vol. 18, Iss. 1, pp. 56-70
Closed Access | Times Cited: 153
The renin-angiotensin-aldosterone system and its therapeutic targets
Katrina M. Mirabito Colafella, Dominique M. Bovée, A.H. Jan Danser
Experimental Eye Research (2019) Vol. 186, pp. 107680-107680
Closed Access | Times Cited: 152
Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage
Peter Kolkhof, Elke Hartmann, Alexius Freyberger, et al.
American Journal of Nephrology (2021) Vol. 52, Iss. 8, pp. 642-652
Open Access | Times Cited: 107
Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression
Sandra Naaman, George L. Bakris
Diabetes Care (2023) Vol. 46, Iss. 9, pp. 1574-1586
Open Access | Times Cited: 106
Role of Renin-Angiotensin-Aldosterone System Activation in Promoting Cardiovascular Fibrosis and Stiffness
Guanghong Jia, Annayya R. Aroor, Michael A. Hill, et al.
Hypertension (2018) Vol. 72, Iss. 3, pp. 537-548
Open Access | Times Cited: 150
Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside
Peter Kolkhof, Frédéric Jaisser, So Young Kim, et al.
Handbook of experimental pharmacology (2016), pp. 271-305
Closed Access | Times Cited: 133
30 YEARS OF THE MINERALOCORTICOID RECEPTOR: The brain mineralocorticoid receptor: a saga in three episodes
Marian Joëls, E. R. de Kloet
Journal of Endocrinology (2017) Vol. 234, Iss. 1, pp. T49-T66
Open Access | Times Cited: 122
Mineralocorticoid Receptor and Cardiovascular Disease
Mathieu Buonafine, Benjamin Bonnard, Frédéric Jaisser
American Journal of Hypertension (2018) Vol. 31, Iss. 11, pp. 1165-1174
Open Access | Times Cited: 102
30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Evolution of the mineralocorticoid receptor: sequence, structure and function
Michael E. Baker, Yoshinao Katsu
Journal of Endocrinology (2017) Vol. 234, Iss. 1, pp. T1-T16
Open Access | Times Cited: 98
Glucocorticoid resistance in chronic diseases
Juan M. Corchado, Matías Monsalves‐Álvarez, Sandra Henríquez, et al.
Steroids (2016) Vol. 115, pp. 182-192
Closed Access | Times Cited: 94
Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria
Sadayoshi Ito, Kenichi Shikata, Masaomi Nangaku, et al.
Clinical Journal of the American Society of Nephrology (2019) Vol. 14, Iss. 8, pp. 1161-1172
Open Access | Times Cited: 94
Pannexin 1 Channels as an Unexpected New Target of the Anti-Hypertensive Drug Spironolactone
Miranda E. Good, Yu‐Hsin Chiu, Ivan K. H. Poon, et al.
Circulation Research (2017) Vol. 122, Iss. 4, pp. 606-615
Open Access | Times Cited: 92
The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure
Nicola Riccardo Pugliese, Stefano Masi, Stefano Taddei
Heart Failure Reviews (2019) Vol. 25, Iss. 1, pp. 31-42
Closed Access | Times Cited: 81
Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials
Ajay Chaudhuri, Husam Ghanim, Pradeep Arora
Diabetes Obesity and Metabolism (2021) Vol. 24, Iss. 3, pp. 365-376
Open Access | Times Cited: 73
Nanostructured Dense Collagen‐Polyester Composite Hydrogels as Amphiphilic Platforms for Drug Delivery
Xiaolin Wang, Olivier Ronsin, Basile Gravez, et al.
Advanced Science (2021) Vol. 8, Iss. 7
Open Access | Times Cited: 68
Aldosterone and Mineralocorticoid Receptor Signaling as Determinants of Cardiovascular and Renal Injury: From Hans Selye to the Present
Murray Epstein
American Journal of Nephrology (2021) Vol. 52, Iss. 3, pp. 209-216
Open Access | Times Cited: 65
Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF
João Pedro Ferreira, Job A.J. Verdonschot, Ping Wang, et al.
JACC Heart Failure (2021) Vol. 9, Iss. 4, pp. 268-277
Open Access | Times Cited: 62
Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders − New perspectives for combination therapy
Peter Kolkhof, Amer Joseph, Ulrich Kintscher
Pharmacological Research (2021) Vol. 172, pp. 105859-105859
Open Access | Times Cited: 56
Roles of Mineralocorticoid Receptors in Cardiovascular and Cardiorenal Diseases
Jonatan Barrera‐Chimal, Benjamin Bonnard, Frédéric Jaisser
Annual Review of Physiology (2022) Vol. 84, Iss. 1, pp. 585-610
Closed Access | Times Cited: 53
Page 1 - Next Page

Scroll to top